Author: claimsbot

1. An implantable prosthesis for repairing a tissue or muscle wall defect near a body structure, the implantable prosthesis comprising:
a patch of repair fabric including a body portion that is constructed and arranged to cover at least a portion of the tissue or muscle wall defect, the patch including an outer periphery and having an oval shape with a major axis and a minor axis, the patch including a first end and an opposite second end and a first side and a second side extending between the first and second ends, the major axis extending from the first end to the second end; and
a member substantially surrounding the body portion of the patch, the member terminating in first and second free ends that are spaced apart to form an interruption located at one of the first and second ends of the patch, the member including an indentation that is adapted to be positioned adjacent the body structure, the indentation formed by a portion of the member deviating inwardly away from the outer periphery and toward the body portion, the indentation being spaced from the interruption and located along the first side or the second side of the patch, the indentation being offset from the minor axis in a direction toward the interruption.
2. The implantable prosthesis according to claim 1, wherein the indentation has a curved shape.
3. The implantable prosthesis according to claim 2, wherein the member has a convex shape along a substantial portion thereof and the indentation has a concave shape.
4. The implantable prosthesis according to claim 1, wherein the interruption is located along the major axis.
5. The implantable prosthesis according to claim 1, wherein the patch includes an obtuse end and an acute end, the obtuse end being larger than the acute end.
6. The implantable prosthesis according to claim 5, wherein the indentation is offset from the minor axis toward the acute end.
7. The implantable prosthesis according to claim 6, wherein the interruption is located at the acute end along the major axis.
8. The implantable prosthesis according to claim 7, wherein the interruption is centered about the major axis.
9. The implantable prosthesis according to claim 1, wherein at least one of the repair fabric and the first and second ends of the member is constructed and arranged to inhibit the first and second ends from protruding through the repair fabric.
10. The implantable prosthesis according to claim 1, wherein the body portion is constructed and arranged to cover at least a portion of the tissue or muscle wall defect in a spread out configuration.
11. The implantable prosthesis according to claim 10, wherein the member is constructed and arranged to help deploy andor hold the body portion in the spread out configuration.
12. The implantable prosthesis according to claim 11, wherein the member has a resiliency that allows the member to deform from an initial shape and then return to the initial shape to return the body portion of the patch to the spread out configuration.
13. The implantable prosthesis according to claim 1, wherein the repair fabric includes a first layer and a second layer, the member being disposed between the first layer and the second layer.
14. The implantable prosthesis according to claim 13, wherein the member is disposed within a channel defined by an inner seam and an outer seam joining the first layer to the second layer.
15. The implantable prosthesis according to claim 13, wherein the first layer has a first shape and the second layer has a second shape that is different from the first shape.
16. The implantable prosthesis according to claim 15, wherein the second layer has a generally annular shape.
17. The implantable prosthesis according to claim 16, wherein the second layer includes an inner edge that follows the shape of the member.
18. The implantable prosthesis according to claim 1, wherein the repair fabric is susceptible to the formation of adhesions with tissue and organs.
19. The implantable prosthesis according to claim 1, wherein the repair fabric has a plurality of interstices that are constructed and arranged to allow tissue ingrowth.
20. The implantable prosthesis according to claim 19, wherein the repair fabric includes at least one layer of mesh fabric.
21. The implantable prosthesis according to claim 1, wherein the member includes a monofilament.
22. The implantable prosthesis according to claim 1, wherein the member includes a single indentation along the entire length thereof.
23. The implantable prosthesis according to claim 1, wherein the outer periphery of the patch is symmetric about the major axis and asymmetric about the minor axis.
24. The implantable prosthesis according to claim 1, wherein the portion of the member forming the indentation has a first end and a second end, and wherein the first end of the portion of the member is located a first distance from the major axis in a direction perpendicular to the major axis and the second end of the portion of the member is located a second distance from the major axis in a direction perpendicular to the major axis, the first distance being greater than the second distance such that the indentation is radially skewed relative to the minor axis.

The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.

1. A method for inspecting a region of interest, comprising:
acquiring data corresponding to a number of horizontal slice images extending through an object of interest;
locating a horizontal slice image from the number of horizontal slice images, the locating step comprising:
computing, for at least two of the horizontal slice images, an amount of solder within each of the at least two horizontal slice images;
reviewing a distribution of the computed amounts of solder; and
based on the review, locating the horizontal slice at a desired position for analyzing a characteristic of the region of interest; and

analyzing the located horizontal slice image for the characteristic, wherein the following equation is used to calculate the amount of solder:
\u2211

gray
=
0

bgd_gray

\u2062
(

background_gray
–
gray

)

*
histogram
\u2061
gray
.
2. The method of claim 1, wherein the characteristic is a defect.
3. The method of claim 1, wherein the characteristic is a padlead interface.
4. The method of claim 1, further comprising synthesizing a vertical slice based on the located horizontal slice.
5. The method of claim 1, wherein the step of computing an amount of solder comprises computing a weighted summation of gray scale data points over a gray scale histogram.
6. The method of claim 1, further comprising selecting the at least two horizontal slice images in accordance with the sampling theorem.
7. The method of claim 1, wherein the object of interest comprises a ball grid array joint comprising a solder ball, and the located horizontal slice represents a horizontal slice passing through the approximate center of the solder ball.
8. The method of claim 1, wherein the step of locating comprises identifying a first peak in the distribution.
9. The method of claim 1, wherein the step of locating comprises determining a most significant peak in the distribution, applying an algorithm to the most significant peak and at least one other point in the distribution, and locating a slice other than a slice associated with the most significant peak.
10. The method of claim 1, wherein the step of locating comprises identifying a noise level and locating a slice having a solder amount which falls below the noise level.
11. The method of claim 1, wherein the step of locating comprises identifying unobstructed anchor devices.
12. The method of claim 1, wherein the data is acquired using tomosynthesis.
13. A method for inspecting a region of interest, comprising:
acquiring data corresponding to a number of horizontal slice images extending through an object of interest;
locating a horizontal slice image from the number of horizontal slice images, the locating step comprising:
computing, for at least two of the horizontal slice images, an amount of solder within each of the at least two horizontal slice images;
determining a most significant peak in the distribution;
applying an algorithm to the most significant peak and at least one other point in the distribution; and
locating a horizontal slice other than a horizontal slice associated with the most significant peak as the horizontal slice at a desired position for analyzing a characteristic of the region of interest; and

analyzing the located horizontal slice image for the characteristic.
14. A method for inspecting a region of interest, comprising:
acquiring data corresponding to a number of horizontal slice images extending through an object of interest;
locating a horizontal slice image from the number of horizontal slice images, the locating step comprising:
computing, for at least two of the horizontal slice images, an amount of solder within each of the at least two horizontal slice images;
reviewing a distribution of the computed amounts of solder;
identifying a noise level; and
locating a slice having a solder amount which falls below the noise level as the horizontal slice at a desired position for analyzing a characteristic of the region of interest; and

analyzing the located horizontal slice image for the characteristic.

1. Acyclic compound represented by General Formula (2):
wherein R1 is the same or different, and each represents a hydrogen atom or a protecting group for a hydroxy group; R2 is the same or different, and each represents a bivalent aromatic hydrocarbon group, a bivalent heterocyclic group, or a derivative group thereof; R4 is the same or different, and each represents a bivalent aromatic hydrocarbon group, a bivalent heterocyclic group, or a derivative group thereof; n is the same or different, and each represents an integer of 1 or more; and m is the same or different, and each represents an integer of 0 or more,
and wherein at least one \u2014(R4)m\u2014 is represented by General Formula (8):
wherein m\u2033 is 1, 2 or 3; and a ring of a repeating unit is a 6-membered heterocyclic aromatic ring having nitrogen.
2. A method for producing a carbon nanoring represented by General Formula (1):
wherein R2 is the same or different, and each represents a bivalent aromatic hydrocarbon group, a bivalent heterocyclic group, or a derivative group thereof; R4 is the same or different, and each represents a bivalent aromatic hydrocarbon group, a bivalent heterocyclic group, or a derivative group thereof; n is the same or different, and each represents an integer of 1 or more; and m is the same or different, and each represents an integer of 0 or more,
and wherein at least one \u2014(R4)m\u2014 is represented by General Formula (8):
wherein m\u2033 is 1, 2 or 3; and a ring of a repeating unit is a 6-membered heterocyclic aromatic ring having nitrogen,
the method comprising a conversion step of: converting cyclohexane rings of a cyclic compound represented by General Formula (2):
wherein R1 is the same or different, and each represents a hydrogen atom or a hydroxyl protecting group; and R2, R4, n and m are as defined above,
into benzene rings.
3. A method for producing a carbon nanoring represented by General Formula (1),
wherein R2 is the same or different, and each represents a bivalent aromatic hydrocarbon group, a bivalent heterocyclic group, or a derivative group thereof; R4 is the same or different, and each represents a bivalent aromatic hydrocarbon group, a bivalent heterocyclic group, or a derivative group thereof; n is the same or different, and each represents an integer of 1 or more; and m is the same or different, and each represents an integer of 0 or more,
the method comprising a coupling step of:
performing coupling reaction of a compound represented by General Formula (3):
wherein X is the same or different, and each represents a halogen atom; R1 is the same or different, and each represents a hydrogen atom or a hydroxyl protecting group; and R2, R4, n and m are as defined above,
and a compound represented by General Formula (4):
wherein Y is the same or different, and each represents a group represented by General Formula (9):
wherein R3 is the same or different, and each represents a hydrogen atom or a C1-C10 alkyl group; and R3 may be bonded to form a ring with adjacent \u2014O\u2014B\u2014O\u2014;
and R1, R2 and n are as defined above,
to form a cyclic compound represented by General Formula (2):
wherein R1, R2, R4, n and m are as defined above;
and a conversion step of converting cyclohexane rings of the cyclic compound into benzene rings.
4. A carbon nanoring represented by General Formula (1):
wherein R2 is the same or different, and each represents a bivalent aromatic hydrocarbon group, a bivalent heterocyclic group, or a derivative group thereof; R4 is the same or different, and each represents a bivalent aromatic hydrocarbon group, a bivalent heterocyclic group, or a derivative group thereof; n is the same or different, and each represents an integer of 1 or more; and m is the same or different, and each represents an integer of 0 or more,
and wherein at least one \u2014(R4)m\u2014 is represented by General Formula (8):
wherein m\u2033 is 1, 2 or 3; and a ring of a repeating unit is a 6-membered heterocyclic aromatic ring having nitrogen.
5. (canceled)
6. (canceled)
7. (canceled)
9. (canceled)
10. (canceled)
11. (canceled)
12. A method for producing a cyclic compound represented by General Formula (2):
wherein R1 is the same or different, and each represents a hydrogen atom or a protecting group for a hydroxy group; R2 is the same or different, and each represents a bivalent aromatic hydrocarbon group, a bivalent heterocyclic group, or a derivative group thereof; R4 is the same or different, and each represents a bivalent aromatic hydrocarbon group, a bivalent heterocyclic group, or a derivative group thereof; n is the same or different, and each represents an integer of 1 or more; and m is the same or different, and each represents an integer of 0 or more,
the method comprising a coupling step of performing coupling reaction of a compound represented by General Formula (3):
wherein X is the same or different, and each represents a halogen atom; and R1, R2, R4, n and m are as defined above,
and a compound represented by General Formula (4):
wherein Y is the same or different, and each represents a group represented by General Formula (9):
wherein R3 is the same or different, and each represents a hydrogen atom or a C1-C10 alkyl group; R3 may be bonded to form a ring with adjacent \u2014O\u2014B\u2014O\u2014,
and R1, R2 and n are as defined above,
to form the cyclic compound represented by General Formula (2).
13. A compound represented by General Formula (3):
wherein X is the same or different, and each represents a halogen atom; R1 is the same or different, and each represents a hydrogen atom or a protecting group for a hydroxy group; R2 each represents a bivalent aromatic hydrocarbon group, a bivalent heterocyclic group, or a derivative group thereof; R4 is the same or different, and each represents a bivalent aromatic hydrocarbon group, a bivalent heterocyclic group, or a derivative group thereof; n is an integer of 1 or more; and m is the same or different, and each represents an integer of 0 or more.
14. A method for producing a compound represented by General Formula (3):
wherein X is the same or different, and each represents a halogen atom; R1 is the same or different, and each represents a hydrogen atom or a protecting group for a hydroxy group; R2 each represents a bivalent aromatic hydrocarbon group, a bivalent heterocyclic group, or a derivative group thereof; R4 is the same or different, and each represents a bivalent aromatic hydrocarbon group, a bivalent heterocyclic group, or a derivative group thereof; n is an integer of 1 or more; and m is the same or different, and each represents an integer of 0 or more,
the method comprising a reaction step of reacting, in the presence of a palladium catalyst, a raw materials containing Compound (10) represented by General Formula (10):
wherein X and R1 are as defined above,
and Compound (11) represented by General Formula (11):
wherein R2 and n are as defined above; and Y is the same or different and each represents a group represented by General Formula (9):
wherein R3 is the same or different, and each represents a hydrogen atom or a C1-C10 alkyl group; and R2 may be bonded to form a ring with adjacent \u2014O\u2014B\u2014O\u2014.
15. A carbon nanoring represented by General Formula (1):
wherein R2 is the same or different, and each represents a bivalent aromatic hydrocarbon group, a bivalent heterocyclic group, or a derivative group thereof; R4 is the same or different, and each represents a bivalent aromatic hydrocarbon group, a bivalent heterocyclic group, or a derivative group thereof; n is the same or different, and each represents an integer of 1 or more; and m is the same or different, and each represents an integer of 0 or more,
and wherein at least one \u2014(R2)n\u2014 is represented by General Formula (5):
wherein n\u2032 is 1 or 2; and p is 1.
16. (canceled)
17. The carbon nanoring according to claim 4, wherein the total number of phenylene, R2, and R4 in the carbon nanoring is 13, 14, 15, 16, 17, 19 or 20.
18. A cyclic compound represented by General Formula (2):
wherein R1 is the same or different, and each represents a hydrogen atom or a protecting group for a hydroxy group; R2 is the same or different, and each represents a bivalent aromatic hydrocarbon group, a bivalent heterocyclic group, or a derivative group thereof; R4 is the same or different, and each represents a bivalent aromatic hydrocarbon group, a bivalent heterocyclic group, or a derivative group thereof; n is the same or different, and each represents an integer of 1 or more; and m is the same or different, and each represents an integer of 0 or more,
and wherein at least one \u2014(R2)n\u2014 is represented by General Formula (5):
wherein n\u2032 is 1 or 2; and p is 1.
19. A method for producing a carbon nanoring represented by General Formula (1):
wherein R2 is the same or different, and each represents a bivalent aromatic hydrocarbon group, a bivalent heterocyclic group, or a derivative group thereof; R4 is the same or different, and each represents a bivalent aromatic hydrocarbon group, a bivalent heterocyclic group, or a derivative group thereof; n is the same or different, and each represents an integer of 1 or more; and m is the same or different, and each represents an integer of 0 or more,
wherein at least one \u2014(R2)n\u2014 is represented by General Formula (5):
wherein n\u2032 is 1 or 2; and p is 1,
the method comprising a conversion step of: converting cyclohexane rings of a cyclic compound represented by General Formula (2):
wherein R1 is the same or different, and each represents a hydrogen atom or a hydroxyl protecting group; and R2, R4, n and m are as defined above,
into benzene rings.

The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.

1. A method of treating a brain or nerve disorder selected from the group consisting of cerebral ischemia, ischemic stroke, hemorrhagic stroke, Alzheimer’s disease, and epilepsy, comprising administering to a patient in need thereof a therapeutically effective amount of a compound of formula (I):
wherein
R1 is hydrogen or alkyl;
each of R2 and R3 is independently selected from hydrogen, alkyl, \u2014COR6, \u2014SO2R7, or substituted or unsubstituted phenyl or benzyl, wherein R6 is alkyl, alkoxy, phenyl, phenyloxy or benzyloxy, each of which is unsubstituted or substituted with halogen, hydroxy, methoxy, ethoxy or nitro, and R7 is unsubstituted or substituted lower alkyl or aryl;
A is \u2014(CH2)n- or \u2014CH2CH\u2550CHCH2\u2014, wherein n is an integer selected from 2 to 4;
R4 is hydrogen and R5 is hydrogen or benzoyl unsubstituted or substituted with one or more of halogen, hydroxy, alkoxy or nitro in benzene ring or when R4 and R5 together with N form a ring,
R4 and R5 form a divalent moiety of
wherein R8 is hydrogen or alkyl;
each of l and m is independently an integer selected from 2 to 4; and
p is an integer of 0 or 1,
or a pharmaceutically acceptable salt thereof
2. The method of claim 1, wherein said disorder is an ischemic or hemorrhagic stroke.
3. The method of claim 1, wherein said disorder is Alzheimer’s disease.
4. The method of claim 1, wherein said disorder is epilepsy.
5. The method of claim 1, wherein:
R1 is hydrogen;
each of R2 and R3 is independently selected from hydrogen, C1-6 alkyl, \u2014COR6, \u2014SO2R7, or substituted or unsubstituted phenyl or benzyl, wherein R6 is alkyl, alkoxy, phenyl, phenyloxy or benzyloxy, each of which is unsubstituted or substituted with halogen, hydroxy, methoxy, ethoxy or nitro, and R7 is unsubstituted or substituted lower alkyl or aryl;
A is \u2014(CH2)n-or \u2014CH2CH\u2550CHCH2-, wherein n is an integer selected from 2 to 4;
R4 is hydrogen and R5 is hydrogen or benzoyl unsubstituted or substituted with one or more of halogen, hydroxy, alkoxy or nitro in benzene ring, or when R4 and R5 together with N form a ring,
R4 and R5 form a divalent moiety of
\u2003wherein R8 is hydrogen or alkyl;
each of l and m is independently an integer selected from 2 to 4; and
p is an integer of 0 or 1.
6. The method of claim 1 wherein the compound is selected from the group consisting of:
3-{3-4-(3-aminopropylamino)butylaminopropyl}-1H-quinazoline-2,4-dione;
3-(3-{4-3-(2,4-dioxo-1,4-dihydro-2H-quinazolin-3-yl)propylaminobutylamino}propyl)-1H-quinazoline-2,4-dione;
N-3-(2,4-dioxo-1,4-dihydro-2H-quinazolin-3-yl)propyl-N-{4-3-(2,4-dioxo-1,4-dihydro-2H-quinazolin-3-yl)propylaminobutyl}acetamide;
N-(4-{acetyl-3-(2,4-dioxo-1,4-dihydro-2H-quinazolin-3-yl)propylamino}butyl)-N-3-(2,4-dioxo-1,4-dihydro-2H-quinazolin-3-yl)propylacetamide;
3-(2,4-dioxo-1,4-dihydro-2H-quinazolin-3-yl)propyl-{4-3-(2,4-dioxo-1,4-dihydro-2H-quinazolin-3-yl)propylaminobutyl}carbamic acid ethyl ester;
N-3-(2,4-dioxo-1,4-dihydro-2H-quinazolin-3-yl)propyl-N-(4-{3-(2,4-dioxo-1,4-dihydro-2H-quinazolin-3-yl)propylmethylamino}butyl)acetamide;
3-{4-3-(2,4-dioxo-1,4-dihydro-2H-quinazolin-3-yl)propylaminobutyl}-1 H-quinazoline-2,4-dione;
N-(3-{4-3-(2,4-dioxo-1,4-dihydro-2H-quinazolin-3-yl)propylaminobutylamino}propyl)-4-hydroxybenzamide;
3-{3-4-({N-3-(2,4-dioxo-1,4-dihydro-2H-quinazolin-3-yl)propyl-N-benzyl}amino)butyl aminopropyl}-1 H-quinazoline-2,4-dione;
N-3-(2,4-dioxo-1,4-dihydro-2H-quinazolin-3-yl)propyl-N-{4-3-(2,4-dioxo-1,4-dihydro-2H- quinazolin-3-yl)propylaminobutyl}benzamide;
3-(2,4-dioxo-1,4-dihydro-2H-quinazolin-3-yl)propyl-{4-3-(2,4-dioxo-1,4-dihydro-2H-quinazolin-3-yl)propylaminobutyl}carbamic acid tert-butyl ester;
N-3-(2,4-dioxo-1,4-dihydro-2H-quinazolin-3-yl)propyl-N-{4-3-(2,4-dioxo-1,4-dihydro-2H-quinazolin-3-yl)propylaminobutyl}methansulfonamide;
N-(4-{benzyl-3-(2,4-dioxo-1,4-dihydro-2H-quinazolin-3-yl)propylamino}butyl)-N-3-(2,4-dioxo-1,4-dihydro-2H-quinazolin-3-yl)propylacetamide;
(4-{acetyl-3-(2,4-dioxo-1,4-dihydro-2H-quinazolin-3-yl)propylamino}butyl)-3-(2,4-dioxo-1,4-dihydro-2H-quinazolin-3-yl)propylcarbamic acid ethyl ester;
3-{3-(4-{N-3-(2,4-dioxo-1,4-dihydro-2H-quinazolin-3-yl)propyl-N-benzylamino}butyl)-N-benzylaminopropyl}-1H-quinazoline-2,4-dione;
3-(2,4-dioxo-1,4-dihydro-2H-quinazolin-3-yl)propyl-(4-{3-(2,4-dioxo-1,4-dihydro-2H-quinazolin-3-yl)propylethoxycarbonylamino}butyl)carbamic acid ethyl ester;
(4-{tert-butoxycarbonyl-3-(2,4-dioxo-1,4-dihydro-2H-quinazolin-3-yl)propylamino}butyl)-3-(2,4-dioxo-1,4-dihydro-2H-quinazolin-3-yl)propylcarbamic acid tert-butyl ester;
N-3-(2,4-dioxo-1,4-dihydro-2H-quinazolin-3-yl)propyl-N-(4-{3-(2,4-dioxo-1,4-dihydro-2H-quinazolin-3-yl)propylmethansulfonylamino}butyl)methansulfonamide;
N- 3-(acetyl-{4-3-(2,4-dioxo-1,4-dihydro-2H-quinazolin-3-yl)propylaminobutyl}amino) propyl-4-hydroxybenzamide;
N-3-(4-{acetyl-3-(2,4-dioxo-1,4-dihydro-2H-quinazolin-3-yl)propylamino}butylamino) propyl-4-hydroxybenzamide;
N-{3-acetyl-(4-{acetyl-3-(2,4-dioxo-1,4-dihydro-2H-quinazolin-3-yl)propylamino}butyl) aminopropyl}-4-hydroxybenzamide;
N-4-(2,4-dioxo-1,4-dihydro-2H-quinazolin-3-yl)butyl-N-3-(2,4-dioxo-1,4-dihydro-2H- quinazolin-3-yl)propylacetamide;
3-(2-{3-2-(2,4-dioxo-1,4-dihydro-2H-quinazolin-3-yl)ethylaminopropylamino }ethyl)-1H-quinazoline-2,4-dione;
3-(3-{3-3-(2,4-dioxo-1,4-dihydro-2H-quinazolin-3-yl)propylaminopropylamino}propyl)-1H-quinazoline-2,4-dione;
3-(3-{4-3-(2,4-dioxo-1,4-dihydro-2H-quinazolin-3-yl)propylamino-2-butenylamino}propyl)-1H-quinazoline-2,4-dione;
(4-{tert-butoxycarbonyl- 3-(1-methyl-2,4-dioxo- 1,4-dihydro-2H-quinazolin-3-yl) propylamino}butyl)-3-(1-methyl-2,4-dioxo-1,4-dihydro-2H-quinazolin-3-yl) propylcarbamic acid tert-butyl ester;
1-methyl-3-(3-{4-3-(1-methyl-2,4-dioxo-1,4-dihydro-2H-quinazolin-3-yl) propylaminobutylamino}propyl)-1H-quinazoline-2,4-dione;
3-(3-{4-3-(1 ,3-dioxo-1,3-dihydro-isoindole-2-yl)propylaminobutylamino }propyl)-1 H-quinazoline-2,4-dione;
3-(3-{2-3-(2,4-dioxo-1,4-dihydro-2H-quinazolin-3-yl)propylaminoethylamino}propyl)-1H-quinazoline-2,4-dione;
3-(2,4-dioxo-1,4-dihydro-2H-quinazolin-3-yl)propyl-(4-{3-(2,4-dioxo-1,4-dihydro-2H-quinazolin-3-yl)propylhexylamino }butyl)carbamic acid tert-butyl ester;
3-3-(4-{N-3-(2,4-dioxo-1,4-dihydro-2H-quinazolin-3-yl)propyl-N-hexylamino}butylamino)propyl-1H-quinazoline-2,4-dione;
(4-{tert-butoxycarbonyl-3-(1-hexyl-2,4-dioxo-1,4-dihydro-2H-quinazolin-3-yl)propylamino}butyl)-3-(1-hexyl-2,4-dioxo-1,4-dihydro-2H-quinazolin-3-yl)propylcarbamic acid tert-butyl ester;
1-hexyl-3-(3-{4-3-(1-hexyl-2,4-dioxo-1,4-dihydro-2H-quinazolin-3-yl) propylaminobutylamino}propyl)-1H-quinazoline-2,4-dione;
3-(2,4-dioxo-1,4-dihydro-2H-quinazolin-3-yl)propyl-(4-{3-(2,4-dioxo-1,4-dihydro-2H-quinazolin-3-yl)propylheptanoylamino }butyl)carbamic acid tert-butyl ester;
3-(2,4-dioxo-1,4-dihydro-2H-quinazolin-3-yl)propyl-{4-3-(2,4-dioxo-1,4-dihydro-2H-quinazolin-3-yl)propylaminobutyl}heptanoic amide;
N-3-(2,4-dioxo-1,4-dihydro-2H-quinazolin-3-yl)propyl-N-{4-3-(2,4-dioxo-1,4-dihydro-2H-quinazolin-3-yl)propylaminobutyl}-2,2,2-trifluoroacetamide;
N-3-(2,4-dioxo-1,4-dihydro-2H-quinazolin-3-yl)propyl-N-{4-3-(2,4-dioxo-1,4-dihydro-2H-quinazolin-3-yl)propyl-(2,2,2-trifluoroacetyl)aminobutyl}-2,2,2-trifluoroacetamide;
N-3-(2,4-dioxo-1,4-dihydro-2H-quinazolin-3-yl)propyl-N-{4-3-(2,4-dioxo-1,4-dihydro-2H-quinazolin-3-yl)propylaminobutyl}-2-methoxyacetamide;
3-(2,4-dioxo-1,4-dihydro-2H-quinazolin-3-yl)propyl-{4-3-(2,4-dioxo-1,4-dihydro-2H-quinazolin-3-yl)propylaminobutyl}carbamic acid benzyl ester;
N-3-(2,4-dioxo-1,4-dihydro-2H-quinazolin-3-yl)propyl-N-{4-3-(2,4-dioxo-1,4-dihydro-2H-quinazolin-3-yl)propylaminobutyl}-4-methylbenzenesulfonamide;
N-3-(2,4-dioxo-1,4-dihydro-2H-quinazolin-3-yl)propyl-N-(4-{3-(2,4-dioxo-1,4-dihydro-2H-quinazolin-3-yl)propyl-4-methylbenzenesulfonylamino }butyl)-4-methylbenzenesulfonamide; and
3-(3-{4 3-(2,5-dioxo-pyrrolidine-1-yl)propylaminobutylamino }propyl)-1H-quinazoline-2,4-dione,
or a pharmaceutically acceptable salt thereof
7. The method of claim 1 wherein the compound is N-3-(2,4-dioxo-1,4-dihydro-2H-quinazolin-3-yl)propyl-N-{4-3-(2,4-dioxo-1,4-dihydro-2H-quinazolin-3-yl)propylaminobutyl}acetamide, or a pharmaceutically acceptable salt thereof.
8. The method of claim 1 wherein the compound is 3-{4-3-(2,4-dioxo-1,4 -dihydro-2H-quinazolin-3-yl)propylaminobutyl}-1H-quinazoline-2,4-dione, or a pharmaceutically acceptable salt thereof.
9. The method of claim 1 wherein the compound is 3-{3 4-({N-3-(2,4-dioxo-1,4-dihydro-2H-quinazolin-3-yl)propyl-N-benzyl}amino)butylaminopropyl}-1H- quinazoline-2,4-dione, or a pharmaceutically acceptable salt thereof.
10. The method of claim 1 wherein the compound is N-3-(acetyl-{4-3-(2,4-dioxo-1,4-dihydro-2H-quinazolin-3-yl)propylaminobutyl}amino)propyl-4-hydroxybenzamide, or a pharmaceutically acceptable salt thereof
11. The method of claim 1 wherein the compound is N-3-(4-{acetyl-3-(2,4-dioxo-1,4-dihydro-2H-quinazolin-3-yl)propylamino}butylamino)propyl-4-hydroxybenzamide, or a pharmaceutically acceptable salt thereof.
12. The method of claim 1 wherein the compound is 3-(2-{3-2-(2,4-dioxo-1,4-dihydro-2H-quinazolin-3-yl)ethylaminopropylamino}ethyl)-1H-quinazoline-2,4-dione, or a pharmaceutically acceptable salt thereof.
13. The method of claim 1 wherein the compound is 3-(2,4-dioxo-1,4-dihydro-2H-quinazolin-3-yl)propyl-(4-{3-(2,4-dioxo-1,4-dihydro-2H-quinazolin-3-yl)propylhexylamino} butyl) carbamic acid tert-butyl ester, or a pharmaceutically acceptable salt thereof.
14. The method of claim 1 wherein the compound is 3-(2,4-dioxo-1,4-dihydro-2H-quinazolin-3-yl)propyl-{4-3-(2,4-dioxo-1,4-dihydro-2H-quinazolin-3-yl)propylaminobutyl}carbamic acid benzyl ester, or a pharmaceutically acceptable salt thereof.
15. The method of claim 1 wherein the compound is N-3-(2,4-dioxo-1,4-dihydro-2H-quinazolin-3-yl)propyl-N-{4-3-(2,4-dioxo-1,4-dihydro-2H-quinazolin-3-yl)propylaminobutyl}-4-methylbenzenesulfonamide, or a pharmaceutically acceptable salt thereof.